Simeprevir: A macrocyclic hcv protease inhibitor

R. Talwani, E. L. Heil, B. L. Gilliam, Zelalem Temesgen

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Simeprevir is a macrocyclic NS3/4A HCV protease inhibitor with potent activity against genotypes 1, 2, 4, 5 and 6 of the hepatitis C virus (HCV). Phase II and III studies of simeprevir combined with pegylated interferon (peg-IFN) and ribavirin (RBV) demonstrated that the combination was safe and effective in HCV genotype 1 patients, with more than 75% of treatment-naive patients attaining a sustained virological response (SVR). Simeprevir is administered once daily as a single 150-mg capsule. It has a moderate drug interaction potential, but less than that of the first-generation HCV protease inhibitors. Based on positive results from the product's phase III clinical program, simeprevir was approved and launched in Japan, the U.S. and Canada in late 2013 for use in combination with peg-IFN/RBV in HCV genotype 1 infections. Phase II interferon-free studies of simeprevir are ongoing.

Original languageEnglish (US)
Pages (from-to)769-779
Number of pages11
JournalDrugs of Today
Issue number12
StatePublished - Dec 2013


  • GT-1
  • Hepatitis C virus
  • Macrolide
  • Simeprevir
  • TMC-435

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Simeprevir: A macrocyclic hcv protease inhibitor'. Together they form a unique fingerprint.

Cite this